Abstract:The growing use of molecular imaging helps to control and monitor dosage for increased safety and effectiveness. Molecular imaging agents become the scientific tools for moving a concept from bench work to clinic product development. This special issue provides original research and review of new trends in molecular imaging agent development. Among clinic molecular imaging modalities, radionuclide imaging technique is the most sensitive and could provide target-specific information. The radiotracer could non-invasively assess disease treatment endpoints which used to rely almost exclusively on biopsies and histopathological assays. L.-H. Shen et al. (Taiwan) reviewed molecular imaging in the diagnosis and management of CNS disorders. F.-L. Kong et al. (USA), N. Tsao et al. (USA), and C.-L. Ho et al. (Taiwan) report pharmacokinetics and dosimetry of molecular imaging compounds in oncology. M.-H. Liao et al. (Taiwan), X. Wang et al. (China), C. Wu et al. (China) and M. Tian et al. (USA) reported that molecular imaging techniques play a major role in the development of novel therapies since they measure target expressions (apoptosis, glycolysis) as well as function, pathway activities, and cell migration in the intact organism. Y.-F. Wang et al. and M.-Y. Chao et al. (Taiwan) described the kit probe for 99mTc-labeling which is crucial for centralized drug process. The kit probe may allow theranostic concept. A theranostic agent would be more accurate in the evaluation of patient response to treatment. The radiotracer could also be used for radionuclide therapy as reported by C. Wang et al. (China). Hybrid molecular imaging modalities (PET/CT, SPECT/CT) provide high-sensitivity functional and high-resolution anatomical imaging which are important in design-personalized treatment. M.-C. Chen et al. (Taiwan) reported the value of using I-131 NP-59 SPECT/CT to diagnose patients with subclinical or atypical features of primary aldosteronism. To proof of concept for molecular biology findings using different imaging modalities (optical, sonography) were described by Z. Pu et al. (China). In summary, molecular imaging enables the comprehensive characterization of therapeutic intervention and can be used in preclinical studies, pharmacokinetic studies, dose-finding studies, and proof-of-concept studies. Molecular imaging technologies promote the discovery and development of personalized medicine. Hong Zhang Mei Tian Carrio Ignasi Zhen Cheng Lie-Hang Shen David J. Yang

Molecular imaging and disease theranostics with renal-clearable optical agents

Renal-clearable Nanoprobes for Optical Imaging and Early Diagnosis of Diseases

Early Tumor Detection Afforded by in Vivo Imaging of Near-Infrared Ii Fluorescence

Engineering Cyanine‐ and Hemicyanine‐Based Probes for Optical Imaging of Kidney Diseases

Developing A Bright Nir-Ii Fluorophore With Fast Renal Excretion And Its Application In Molecular Imaging Of Immune Checkpoint Pd-L1

Molecular Image-Guided Theranostic and Personalized Medicine 2013

Near-infrared fluorescent molecular probes for imaging and diagnosis of nephro-urological diseases

Multivalent supramolecular fluorescent probes for accurate disease imaging

Molecular imaging of renal cell carcinomas: ready for prime time

Imaging in Renal Cell Carcinoma Detection

Molecular optical imaging probes for early diagnosis of drug-induced acute kidney injury

Renal clearing carbon dots-based near-infrared fluorescent super-small nanoprobe for renal imaging

Near-Infrared Fluorescence Probes for Monitoring and Diagnosing Nephron-Urological Diseases

Optical Molecular Probes for Imaging and Early Diagnosis of Acute Kidney Injury

Non-invasive molecular imaging of kidney diseases

Radiolabeled Polyoxometalate Clusters: Kidney Dysfunction Evaluation and Tumor Diagnosis by Positron Emission Tomography Imaging

Optical Molecular Imaging for Tumor Detection and Image-Guided Surgery.

Recent Advances in Renal Clearable Inorganic Nanoparticles for Cancer Diagnosis

Renal-clearable Macromolecular Reporter for Near-infrared Fluorescence Imaging of Bladder Cancer.

Engineering of Kidney‐Targeting Fluorophores with Tunable Emission from NIR‐I to NIR‐II for Early Diagnosis of Kidney Disease

High-Performance Renal Imaging With A Radiolabeled Non-Excretable Chimeric Fusion Protein